Literature DB >> 26271354

Prescription Opioid and Benzodiazepine Use After Road Traffic Injury.

Janneke Berecki-Gisolf, Behrooz Hassani-Mahmooei, Alex Collie, Roderick McClure.   

Abstract

BACKGROUND: Motor vehicle crash victims with physical injury are likely to receive prescription opioids and benzodiazepines. Potential mental trauma and lack of primary treating physician contribute to the risk of adverse opioid outcomes for this group. The purpose of this study is to characterise opioid and benzodiazepine prescribing after road traffic injury.
METHOD: Individuals who claimed Transport Accident Commission compensation for a noncatastrophic injury that occurred between 2010 and 2012 in Victoria, Australia and who provided consent for pharmaceutical benefits scheme (PBS) linkage were included (n = 734). PBS records dating between 12 months preinjury and 18 months postinjury were provided by the Department of Human Services.
RESULTS: In the year before injury, 10.5% of participants received prescription opioids; after injury, 45.1% of hospitalized and 21.1% of nonhospitalized participants received opioids. Benzodiazepines were used by 4.8% preinjury, and 7.0% and 7.4% postinjury (with and without hospitalization, respectively). Postinjury, 39% of opioid use and 73% of benzodiazepine use was potentially unrelated to the injury.
CONCLUSIONS: Prescription opioid and benzodiazepine before road traffic injury was substantial: the significance of postinjury prescription drug use cannot be established without taking preinjury use into account. It may be beneficial for pain medication to be managed by a pain treatment coordinator, in this injured population with high rates of pre-existing opioid and benzodiazepine use.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26271354     DOI: 10.1111/pme.12890

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  7 in total

1.  Gender Differences in Pain Experience and Treatment after Motor Vehicle Collisions: A Secondary Analysis of the CRASH Injury Study.

Authors:  Tracy E Madsen; Samuel McLean; Wanting Zhai; Sarah Linnstaedt; Michael C Kurz; Robert Swor; Phyllis Hendry; David Peak; Christopher Lewandowski; Claire Pearson; Brian O'Neil; Elizabeth Datner; David Lee; Francesca Beaudoin
Journal:  Clin Ther       Date:  2018-01-20       Impact factor: 3.393

2.  Do Injured Workers Receive Opioid Prescriptions Outside the Workers' Compensation System?: The Case of Private Group Health Insurances.

Authors:  Abay Asfaw; Brian Quay; Chia-Chia Chang
Journal:  J Occup Environ Med       Date:  2020-09       Impact factor: 2.162

Review 3.  Connections Between Opioids and Road Injury: Linkage of Prescription Monitoring and Crash Databases.

Authors:  Rebecca B Naumann; Kristin Shiue; Amin Mohamadi Hezaveh; Stephen W Marshall; Christopher R Cherry
Journal:  Am J Prev Med       Date:  2019-12-19       Impact factor: 5.043

4.  Management of Whiplash Associated Disorders in Australian general practice.

Authors:  Jane Nikles; Michael Yelland; Clare Bayram; Graeme Miller; Michele Sterling
Journal:  BMC Musculoskelet Disord       Date:  2017-12-29       Impact factor: 2.362

5.  A comparison of opioids and benzodiazepines dispensing in Australia.

Authors:  M Mofizul Islam; Dennis Wollersheim
Journal:  PLoS One       Date:  2019-08-19       Impact factor: 3.240

6.  Prognostic Role of Demographic, Injury and Claim Factors in Disabling Pain and Mental Health Conditions 12 Months after Compensable Injury.

Authors:  Thi L Nguyen; Katharine S Baker; Liane Ioannou; Behrooz Hassani-Mahmooei; Stephen J Gibson; Alex Collie; Jennie Ponsford; Peter A Cameron; Belinda J Gabbe; Melita J Giummarra
Journal:  Int J Environ Res Public Health       Date:  2020-10-07       Impact factor: 3.390

7.  Self-reported Dysphagia and Pharyngeal Volume Following Whiplash Injury.

Authors:  D Stone; E C Ward; H Bogaardt; R Heard; B Martin-Harris; A C Smith; J M Elliott
Journal:  Dysphagia       Date:  2021-01-01       Impact factor: 2.733

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.